Please use this identifier to cite or link to this item:
Title: Drug Repurposing for Triple-Negative Breast Cancer
Authors: Ávalos-Moreno, Marta
López-Tejada, Araceli
Blaya-Cánovas, Jose L.
Cara-Lupiañez, Francisca E.
González-González, Adrián
Lorente, Jose A.
Sánchez-Rovira, Pedro
Granados-Principal, Sergio
metadata.dc.contributor.authoraffiliation: [Ávalos-Moreno,M; López-Tejada,A; Blaya-Cánovas,JL; Cara-Lupiañez,FE; González-González,A; Lorente,JA; Granados-Principal,S] GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain. [López-Tejada,A; Blaya-Cánovas,JL; Cara-Lupiañez,FE; González-González,A; Sánchez-Rovira,P; Granados-Principal,S] UGC de Oncología Médica, Complejo Hospitalario de Jaén, Jaén, Spain. [Lorente,JA] Department of Legal Medicine, School of Medicine—PTS—University of Granada, Granada, Spain.
Keywords: Triple-negative breast cancer;Personalized medicine;Computational methods;Drug repurposing;Clinical trials;Cancer stem cells;Neoplasias de la mama triple negativas;Medicina de precisión;Reposicionamiento de medicamentos;Ensayos clínicos como asunto;Células madre neoplásicas
metadata.dc.subject.mesh: Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Drug Discovery::Drug Repositioning
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic
Medical Subject Headings::Anatomy::Cells::Stem Cells::Neoplastic Stem Cells
Medical Subject Headings::Chemicals and Drugs::Pharmaceutical Preparations::Drugs, Investigational
Medical Subject Headings::Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biology::Computational Biology::Systems Biology
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Drug Discovery
Medical Subject Headings::Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Biochemical Processes::Signal Transduction
Medical Subject Headings::Information Science::Information Science::Medical Informatics::Medical Informatics Applications::Information Storage and Retrieval::Data Mining
Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence
Issue Date: 29-Oct-2020
Publisher: MDPI
Citation: Avalos-Moreno M, López-Tejada A, Blaya-Cánovas JL, Cara-Lupiañez FE, González-González A, Lorente JA, et al. Drug Repurposing for Triple-Negative Breast Cancer. J Pers Med. 2020 Oct 29;10(4):200
Abstract: Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer which presents a high rate of relapse, metastasis, and mortality. Nowadays, the absence of approved specific targeted therapies to eradicate TNBC remains one of the main challenges in clinical practice. Drug discovery is a long and costly process that can be dramatically improved by drug repurposing, which identifies new uses for existing drugs, both approved and investigational. Drug repositioning benefits from improvements in computational methods related to chemoinformatics, genomics, and systems biology. To the best of our knowledge, we propose a novel and inclusive classification of those approaches whereby drug repurposing can be achieved in silico: structure-based, transcriptional signatures-based, biological networks-based, and data-mining-based drug repositioning. This review specially emphasizes the most relevant research, both at preclinical and clinical settings, aimed at repurposing pre-existing drugs to treat TNBC on the basis of molecular mechanisms and signaling pathways such as androgen receptor, adrenergic receptor, STAT3, nitric oxide synthase, or AXL. Finally, because of the ability and relevance of cancer stem cells (CSCs) to drive tumor aggressiveness and poor clinical outcome, we also focus on those molecules repurposed to specifically target this cell population to tackle recurrence and metastases associated with the progression of TNBC.
metadata.dc.identifier.doi: 10.3390/jpm10040200
ISSN: 2075-4426 (Online)
Appears in Collections:01- Artículos - Complejo Hospitalario de Jaén
01- Artículos - GENYO. Centro Pfizer-Andalucía de Genómica e Investigación Oncológica

Files in This Item:
File Description SizeFormat 
AvalosMoreno_DrugRepurposing.pdfRevisión2,25 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons